ERBB2 and breast cancer: Li et al.132 developed a novel HER2-specific exosome-T vaccine using polyclonal CD4+ T cells armed with HER2-specific exosomes released from DC and demonstrated its therapeutic effect against HER2+ BC in double-transgenic HER2/HLA-A2 mice.